Details for Patent: 11,975,006

Which drugs does patent 11,975,006 protect, and when does it expire?

Patent 11,975,006 protects TADLIQ and is included in one NDA.

This patent has nine patent family members in nine countries.

Summary for Patent: 11,975,006

Title:	Liquid oral formulations for tadalafil
Abstract:	The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.
Inventor(s):	Jinal Pandya, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Hiren Pansuriya
Assignee:	Liqmeds Worldwide Ltd
Application Number:	US18/308,723
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,975,006
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 11,975,006

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cmp Dev Llc	TADLIQ	tadalafil	SUSPENSION;ORAL	214522-001	Jun 17, 2022		RX	Yes	Yes	11,975,006		Y			TADLIQ IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE ABILITY

International Family Members for US Patent 11,975,006

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018397436
Brazil	112020012986
Canada	3086881